Big Health Promotes FDA-Cleared Digital Insomnia Therapy SleepioRx to Providers

According to a recent LinkedIn post from Big Health, the company is promoting SleepioRx, an FDA-cleared digital cognitive behavioral therapy for insomnia (CBT-I) that aims to serve as a scalable, first-line treatment alternative to medication. The post positions SleepioRx as a solution that can be integrated into real-world clinical workflows to broaden access to evidence-based insomnia care.

The post highlights an upcoming 30-minute webinar on Friday, May 15 at 12:30 PM ET featuring Jenna Carl, PhD, and Dani Bradley. The session is described as covering the role of digital CBT-I in the current insomnia care landscape and how providers are using SleepioRx in practice.

Additional topics in the webinar, according to the post, include clinical workflows, referral options, and patient experience insights. The post also notes that cost, coverage, and billing considerations for SleepioRx will be discussed, which may be of interest to payers and providers evaluating reimbursement and adoption.

For investors, the emphasis on FDA clearance and integration into clinical workflows suggests Big Health is positioning SleepioRx as a reimbursable, clinically validated digital therapeutic rather than a direct-to-consumer wellness app. If adoption by providers and payers accelerates, this could support recurring revenue streams and strengthen the company’s competitive position in the digital health and behavioral sleep medicine markets.

The focus on scalability and first-line treatment positioning indicates a strategy aimed at capturing share from traditional pharmacologic insomnia treatments. Successful execution could increase Big Health’s addressable market and enhance its value proposition to health systems and insurers, though ultimate financial impact will depend on demonstrated clinical outcomes, reimbursement levels, and provider uptake.